keyword
MENU ▼
Read by QxMD icon Read
search

ABVD

keyword
https://www.readbyqxmd.com/read/27921440/fertility-preservation-before-an-abvd-protocol-no-new-evidence-to-support-changing-the-recommendations
#1
Catherine Poirot, Nathalie Dhedin, Pauline Brice
No abstract text is available yet for this article.
December 6, 2016: Future Oncology
https://www.readbyqxmd.com/read/27919174/outcome-of-pediatric-advanced-hodgkin-lymphoma-treated-with-abvd-and-predictors-of-inferior-survival-a-multicenter-study-of-186-patients
#2
Sainath Bhethanabhotla, Sandeep Jain, Gauri Kapoor, Amita Mahajan, Anita Chopra, Sreenivas Vishnubhatla, Sameer Bakhshi
Clinical stage alone is used for risk stratification in treatment of pediatric advanced Hodgkin lymphoma (HL). To identify other risk factors, we collected data from three tertiary centers on 186 patients with advanced stage (IIB-IV) consecutively treated with Adriamycin, bleomycin, vinblastine, Dacarbazine (ABVD) chemotherapy ± radiotherapy. Freedom from treatment failure (FFTF) and overall survival (OS) were end points. With median follow-up period of 57.9 months (range: 1-151 months), five-year FFTF and OS was 84...
December 6, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27913497/response-adapted-frontline-therapy-for-hodgkin-lymphoma-are-we-there-yet
#3
Peter W M Johnson
Treating Hodgkin lymphoma by using chemotherapy with or without radiotherapy is highly successful, with substantially fewer deaths from lymphoma than from other causes in recent studies of both early-stage and advanced-stage disease. Long-term toxicity is a major consideration in this context, and recent trials have used functional imaging with [(18)F]fluorodeoxyglucose (FDG) positron emission tomography early in the course of treatment (interim PET) to assess response and modulate subsequent therapy. In early-stage disease, this has allowed omission of consolidation radiotherapy after a good response to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy, and trials have shown that this can be done without detriment to overall survival, despite a small increase in rates of recurrence of ∼5%...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27812252/chemotherapy-and-radiation-induced-pulmonary-dysfunction-in-hodgkin-lymphoma-patients
#4
Sebnem Izmir Guner, Mustafa Teoman Yanmaz, Ahmet Selvi, Cigdem Usul
Although the deterioration in pulmonary functions is a well-known important problem due to the treatment of the Hodgkin's lymphoma patients, the immediate and long term effects of the therapy and its distinctive components were not shown clearly yet. We planned to investigate effects of multiple agent chemotherapy and/or radiotherapy to pulmonary functions immediately and thereafter and the possible effects of the managing this situation. 34 patients were included the study. The patients were evaluated for peak expiratory flow (PEF), forced expiratory volume in 1 s (FEV1), forced expiratory vital capacity (FVC), mean total lung capacity (TLC) values, FEV1/FVC ratio, diffusing capacity for carbonmonoxide (DLco), diffusing capacity for carbonmonoxide corrected for hemoglobin concentration (DLCO) before and at 1, 6 and 12 months after the initiation of the treatment...
December 2016: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/27810161/impact-of-hodgkin-or-non-hodgkin-lymphoma-and-their-treatments-on-sperm-aneuploidy-a-prospective-study-by-the-french-cecos-network
#5
Guillaume Martinez, Marie Walschaerts, Marine Le Mitouard, Remi Borye, Claire Thomas, Jacques Auger, Isabelle Berthaut, Florence Brugnon, Myriam Daudin, Nathalie Moinard, Célia Ravel, Jacqueline Saias, Ethel Szerman, Nathalie Rives, Sylviane Hennebicq, Louis Bujan
OBJECTIVE: To assess sperm production and aneuploidy in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) before and after treatments. DESIGN: Multicenter, prospective, longitudinal study of lymphoma patients analyzed before treatment and after 3, 6, 12, and 24 months. SETTING: University hospitals. PATIENT(S): Forty-five HL and 13 NHL patients were investigated before and after treatment. Treatment regimens were classified in two groups: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with or without (±) radiotherapy, and CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)/MOPP-ABV (mechlorethamine, oncovin, procarbazine, prednisone-doxorubicin, bleomycin, vinblastine)...
October 31, 2016: Fertility and Sterility
https://www.readbyqxmd.com/read/27758822/mediastinal-grey-zone-lymphoma-clinico-pathological-characteristics-and-outcomes-of-99-patients-from-the-lysa
#6
Clémentine Sarkozy, Thierry Molina, Hervé Ghesquières, Anne-Sophie Michallet, Jehan Dupuis, Diane Damotte, Franck Morsschauser, Marie Parrens, Laurent Martin, Peggy Dartigues, Aspasia Stamatoullas, Pierre Hirsch, Betina Fabiani, Krimo Bouabdallah, Maria Gomes da Silva, Marie Maerevoet, Camille Laurent, Bertrand Coiffier, Gilles Salles, Alexandra Traverse-Glehen
Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature. We report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis. Cases were defined as classical Hodgkin lymphoma-like morphology (64.6%) with primary mediastinal B cell lymphoma immunophenotype, primary mediastinal B cell lymphoma-like morphology (30...
October 6, 2016: Haematologica
https://www.readbyqxmd.com/read/27754902/post-treatment-pet-ct-rather-than-interim-pet-ct-using-deauville-criteria-predicts-outcome-in-pediatric-hodgkin-lymphoma-a-prospective-study-comparing-pet-ct-versus-conventional-imaging
#7
Sameer Bakhshi, Sainath Bhethanabhotla, Rakesh Kumar, Krishankant Agarwal, Punit Sharma, Sanjay Thulkar, Arun Malhotra, Deepa Dhawan, Sreenivas Vishnubhatla
BACKGROUND: Data about significance of (18)F-FDG positron emission tomography (PET) at interim assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited. METHODS: Patients (≤18 years) with HL were prospectively evaluated with contrast-enhanced computed tomography (CECT) and PET combined with low-dose CT(PET-CT) at baseline, post 2 cycles of chemotherapy and post completion of treatment. Revised international working group criteria (RIW) and Deauville (DA) five point-scale for response assessment by PET-CT were used...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27742539/does-bleomycin-lung-toxicity-increase-the-risk-of-radiation-pneumonitis-in-hodgkin-lymphoma
#8
Zeinab Abou Yehia, George N Mikhaeel, Grace Smith, Chelsea C Pinnix, Sarah A Milgrom, Chad Tang, Wen Jiang, Michelle A Fanale, Yasuhiro Oki, JoAnn H Shank, Trisha Horace, Jay Reddy, Mani Akhtari, Jillian R Gunther, Tina Suki, Pamela K Allen, Shryll Turner, Osama Mawlawi, Bouthaina S Dabaja
PURPOSE: Bleomycin pulmonary toxicity (BPT) is a well-known complication of treatment in patients with Hodgkin lymphoma (HL). We undertook the present study to investigate the risk of radiation pneumonitis (RP) in the setting of BPT and to determine the need for delay or omission of radiation therapy (RT) in these patients. METHODS AND MATERIALS: We identified 123 HL patients treated with ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) followed by RT to the chest from January 2009 to December 2014...
December 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27733075/the-number-of-tumor-infiltrating-t-cell-subsets-in-lymph-nodes-from-patients-with-hodgkin-lymphoma-is-associated-with-the-outcome-after-first-line-abvd-therapy
#9
Sara Alonso-Álvarez, Maria Belén Vidriales, Maria Dolores Caballero, Oscar Blanco, Noemí Puig, Alejandro Martin, Maria Jesús Peñarrubia, Esther Zato, Josefina Galende, Abelardo Bárez, Miguel Alcoceba, Alberto Orfão, Marcos González, Ramón García-Sanz
Prognostic factors in Hodgkin lymphoma (HL) still fail to accurately identify high-risk patients. Tumor microenvironment in HL is a current focus of research for risk definition but few studies have focused on infiltrating lymphocytes. Here, we analyzed the number of tumor infiltrating lymphocytes by flow cytometry in diagnostic biopsies from 96 HL homogeneously treated patients with ABVD with or without radiotherapy. Most lymph node cells were lymphocytes (90 ± 17), with a median T/B/NK distribution of 74%/26%/0...
October 12, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27692305/the-combined-role-of-biomarkers-and-interim-pet-scan-in-prediction-of-treatment-outcome-in-classical-hodgkin-s-lymphoma-a-retrospective-european-multicentre-cohort-study
#10
Claudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi, Patrizia Agati, Claudio Tripodo, Fabio Fuligni, Maria Teresa Sista, Stefano Fanti, Alberto Biggi, Umberto Vitolo, Luigi Rigacci, Francesco Merli, Caterina Patti, Alessandra Romano, Alessandro Levis, Livio Trentin, Caterina Stelitano, Anna Borra, Pier Paolo Piccaluga, Stephen Hamilton-Dutoit, Peter Kamper, Jan Maciej Zaucha, Bogdan Małkowski, Waldemar Kulikowski, Joanna Tajer, Edyta Subocz, Justyna Rybka, Christian Steidl, Alessandro Broccoli, Lisa Argnani, Randy D Gascoyne, Francesco d'Amore, Pier Luigi Zinzani, Stefano A Pileri
BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease. METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to Dec 31, 2012...
October 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27688147/bleomycin-induced-skin-toxicity-is-it-always-flagellate-erythema
#11
Shailendra Prasad Verma, Arunkumar Subbiah, Vinod Kolar Vishwanath, Tarun Kumar Dutta
Bleomycin-induced skin toxicity is a rare and unique complication. We report a 35-year-old man with nodular lymphocytic predominant Hodgkin's lymphoma, stage IVB, who was started on adriamycin, bleomycin, vinblastin and dacarbazine (ABVD) chemotherapy. He developed pruritic hyperpigmented, patchy skin lesions on the neck, back, chest and thighs after IA cycle of ABVD chemotherapy. Lesions were not typical flagellate rash but hyperpigmented, patchy and mildly pruritic lesions over the trunk and proximal extremities...
2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27675801/treatment-of-early-stage-unfavorable-hodgkin-lymphoma-efficacy-and-toxicity-of-4-versus-6-cycles-of-abvd-chemotherapy-with-radiation
#12
J R Gunther, M Fanale, J Reddy, M Akhtari, G L Smith, C C Pinnix, S A Milgrom, Z Abou Yehia, E M Osborne, O R Mawlawi, P K Allen, B Dabaja
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27630312/strong-kdm4b-and-kdm4d-expression-associates-with-radioresistance-and-aggressive-phenotype-in-classical-hodgkin-lymphoma
#13
Hamid Bur, Kirsi-Maria Haapasaari, Taina Turpeenniemi-Hujanen, Outi Kuittinen, Päivi Auvinen, Katja Marin, Ylermi Soini, Peeter Karihtala
BACKGROUND: Epigenetic regulators, including Jumonji domain 2 (JMJD2/KDM4) proteins are involved in post-translational modification of histone demethylation and have a major role in carcinogenesis of many solid tumors. MATERIALS AND METHODS: We assessed immunohistochemically the expression of lysine (K)-specific demethylase 4 (KDM4)A, KDM4B and KDM4D in tumors from 91 patients of adriamycin, bleomycin, vinblastine, darcabazine (ABVD)-treated classical Hodgkin lymphoma...
September 2016: Anticancer Research
https://www.readbyqxmd.com/read/27539369/hodgkin-lymphoma-a-negative-interim-pet-cannot-circumvent-the-need-for-end-of-treatment-pet-evaluation
#14
Charles Mesguich, Anne-Laure Cazeau, Krimo Bouabdallah, Pierre Soubeyran, Martine Guyot, Noël Milpied, Laurence Bordenave, Elif Hindié
We examined the outcome of a cohort of patients with Hodgkin lymphoma (HL) in order to assess if fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) at the end of treatment (end-PET) can be omitted when the interim PET (int-PET) is negative. Seventy-six ABVD(adriamycin, bleomycin, vinblastine, dacarbazine)-treated patients were retrospectively included. No change in treatment was made on the basis of int-PET results. Suspicious foci on end-PET received biopsy confirmation whenever possible...
November 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27531149/comparison-of-the-efficiency-of-abvd-versus-beacopp-for-hodgkin-lymphoma-treatment-a-meta-analysis
#15
REVIEW
Yanxia Jiang, Yan Chen, Ruibin Huang, Guoan Chen
To compare the efficiency of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) against that of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) for treating Hodgkin lymphoma (HL). An extensive English-language literature retrieval on clinical outcomes after treatment by ABVD versus BEACOPP was conducted on Medline, PubMed, and Embase through the period ending December 2015. Odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was pooled based on the heterogeneity across individual studies...
October 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27519911/osteonecrosis-detected-by-whole-body-magnetic-resonance-in-patients-with-hodgkin-lymphoma-treated-by-beacopp
#16
Domenico Albano, Caterina Patti, Ludovico La Grutta, Emanuele Grassedonio, Antonino Mulè, Giuseppe Brancatelli, Roberto Lagalla, Massimo Midiri, Massimo Galia
OBJECTIVES: The purpose of our retrospective review of prospectively acquired Whole Body Magnetic Resonance (WB-MRI) scans was to assess the incidence of osteonecrosis in patients who received different chemotherapies. METHODS: We evaluated the WB-MRI scans performed on 42 patients with Hodgkin Lymphoma treated by three chemotherapy regimens (6ABVD, 2ABVD + 4BEACOPP, 2ABVD + 8BEACOPP), excluding patients with the main risk factors for osteonecrosis. RESULTS: Six out of seven patients (86 %) who received eight BEACOPP and one out of five patients (20 %) treated by four BEACOPP presented osteonecrosis, with a statistically significant difference of frequency between the two groups of patients (p < 0...
August 13, 2016: European Radiology
https://www.readbyqxmd.com/read/27504392/primary-hodgkin-s-lymphoma-of-the-sternum-report-of-a-case-and-review-of-the-literature
#17
REVIEW
Ankur Jain, Naresh Gupta
Sternal masses present a unique diagnostic challenge in clinical practice. A wide array of differential diagnosis of a sternal mass includes osteomyelitis, tuberculosis, eosinophilic granuloma, sarcoma and lymphoma (usually Non-Hodgkin's) amongst others. Sternum is a rare site of Hodgkin's lymphoma and is usually misdiagnosed as tuberculosis or eosinophilic granuloma on routine histopathology. This delayed diagnosis culminates in death of patients. We report a 30-year-old lady who presented with swelling in upper part of chest wall since 1 month...
June 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27496308/treatment-of-advanced-stage-hodgkin-lymphoma
#18
REVIEW
Theodoros P Vassilakopoulos, Peter W M Johnson
There is now good evidence that the escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) is more effective in controlling advanced-stage Hodgkin lymphoma (HL) than the widely used ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine), but the extra efficacy comes at the expense of both short- and long-term toxicity, and there is debate as to whether overall survival is affected. Baseline prognostic factors have proven of limited utility for determining which patients require more intensive therapy and recent studies have sought to use interim fluoro-deoxyglucose positron emission tomography (FDG-PET) evaluation as a means to guide the modulation of treatment, both upwards and downwards in intensity...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496307/treatment-of%C3%A2-early-stage-hodgkin-lymphoma
#19
REVIEW
Andreas Engert, John Raemaekers
Hodgkin lymphoma (HL) has become one of the best curable malignancies today. This is particularly true for patients with early-stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small-field radiotherapy. More recent clinical trials such as the German Hodgkin Study Group (GHSG) HD10 study demonstrated, that even two cycles of ABVD followed by 20 Gy involved-field radiation therapy (IF-RT) are sufficient and result in more than 90% of patients being cured...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27492260/lymphoma-secondary-to-congenital-and-acquired-immunodeficiency-syndromes-at-a-turkish-pediatric-oncology-center
#20
Hikmet G Tanyildiz, Handan Dincaslan, Gulsan Yavuz, Emel Unal, Aydan Ikinciogulları, Figen Dogu, Nurdan Tacyildiz
The prevalence of lymphoma in primary immunodeficiency cases and autoimmune diseases, as well as on a background of immunodeficiency following organ transplants, is increasing. The lymphoma treatment success rate is known to be a low prognosis. Our study aimed to emphasize the low survival rates in immunodeficient vs. immunocompetent lymphoma patients and also to investigate the effect of rituximab in patients with ataxia telangiectasia and other immunodeficiencies. We summarized the clinical characteristics and treatment results of 17 cases with primary immunodeficiency that developed non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) retrospectively...
October 2016: Journal of Clinical Immunology
keyword
keyword
71275
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"